Related Experiment Video
Updated: Oct 19, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Is it Time for Single-Pill Combinations in Dyslipidemia?
François Schiele1,2, Leopoldo Pérez de Isla3,4, Marcello Arca5
1Department of Cardiology, University Hospital Besancon, 25000, Besancon, France. francois.schiele@univ-fcomte.fr.
Summary
Low rates of low-density lipoprotein cholesterol (LDL-C) control persist despite available therapies. Single-pill combinations improve adherence and LDL-C goal achievement by simplifying treatment regimens.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Despite effective lipid-lowering therapies (LLTs), population-level low-density lipoprotein cholesterol (LDL-C) control remains suboptimal in real-world settings.
- Optimal outcomes are linked to higher-intensity, earlier, and longer-term LLT, yet clinical practice often falls short of maximizing treatment exposure.
Purpose of the Study:
- To evaluate strategies for increasing LLT exposure and improving LDL-C control, addressing barriers like therapeutic inertia and poor adherence.
- To highlight the role of single-pill combinations in simplifying treatment and enhancing patient adherence.
Main Methods:
- Review of European Society of Cardiology guidelines for stepwise LLT optimization.
- Analysis of evidence from randomized controlled trials comparing ezetimibe addition versus statin dose-doubling.
- Assessment of the impact of single-pill combinations versus free associations on adherence and goal attainment.
Main Results:
- Adding ezetimibe to statins proved more effective than doubling statin doses, leading to better LDL-C goal achievement and fewer treatment discontinuations.
- Combination LLT strategies significantly increase overall treatment exposure.
- Single-pill combinations demonstrated superior adherence rates and higher percentages of patients reaching their LDL-C goals compared to free-dose associations.
Conclusions:
- Stepwise LLT optimization, including adding ezetimibe and PCSK9 inhibitors, is recommended but often limited to statin dose increases.
- Therapeutic inertia and poor adherence, influenced by pill burden and complexity, are key barriers to effective LLT.
- Single-pill combinations offer a practical solution to intensify LLT without increasing complexity, thereby improving adherence and LDL-C control.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
968
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
968
01:26Atherosclerosis III: Management
67
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
67
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
31
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
31
01:27Coronary Artery Disease V: Interprofessional Care
71
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
21
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
21
01:27Combined Effects of Drugs: Synergism
5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
5.1K